Stratec, DE000STRA555

mwb research downgraded Stratec stock to Sell at EUR 21.00 target

Published on 10/13/2026 at 05:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached EUR 59.10 million, up 2.40 percent year over year. Third-quarter results due November 5, 2026 will shape Stratec stock.

Key points in brief

  • mwb research downgraded Stratec stock to Sell on September 17, 2026 and kept its EUR 21.00 target.
  • Second-quarter revenue rose 2.40 percent year over year to EUR 59.10 million.
  • Stratec closed at EUR 23.45 on Xetra on October 12, 2026, with third-quarter results due November 5, 2026.
Isometrische 3D-Grafik der Wertschöpfungskette von Laborentwicklung bis Versand
Stratec SE (DE000STRA555) deckt die gesamte Wertschöpfungskette ab, illustriert in dieser isometrischen 3D-Prozessgrafik, Illustration mit AI erstellt.

Stratec (ISIN DE000STRA555) had been downgraded by mwb research from Hold to Sell on September 17, 2026, while the research firm kept its EUR 21.00 price target. The note linked the weaker stance to execution risks despite a stronger second quarter.

Second quarter showed recovery

According to FinanzNachrichten reporting on the September 17, 2026 note, Stratec's second-quarter revenue rose 2.40 percent year over year to EUR 59.10 million. The adjusted EBIT margin reached 11.90 percent, while the analysis said customer ordering remained volatile.

That combination leaves the company with a demanding second half of 2026. mwb research calculated that second-half revenue of EUR 149.00 million to EUR 161.00 million would be required to meet the full-year outlook, equal to growth of 12.00 percent to 22.00 percent over the second half of 2025.

What the downgrade means for 2026

The central issue is execution rather than the second-quarter direction. Stratec's Q2 operating result improved to EUR 5.57 million from EUR 2.25 million in the comparable period, according to Boersengefluester on September 15, 2026. The improvement produced an EBIT margin of 9.40 percent in that report, but demand volatility leaves less room for operational delays.

Three dated developments

On August 14, 2026, Stratec reported second-quarter revenue of EUR 59.10 million and adjusted EBIT of EUR 5.57 million, as summarized by Boersengefluester. On September 15, 2026, the same analysis highlighted the company's 2026 outlook for mid- to high-single-digit currency-adjusted revenue growth and an adjusted EBIT margin near 10.00 percent. On September 17, 2026, FinanzNachrichten reported the Hold-to-Sell downgrade with the EUR 21.00 target unchanged.

Next dates carry the test

Stratec's third-quarter figures are listed for November 5, 2026 in the events table published by Boersengefluester. A separate Yahoo Finance events listing gives November 12, 2026 as the next earnings date, making the November reporting window the next quantified test of the recovery.

Xetra close remains the reference

Stratec's last Xetra price was EUR 23.45 on October 12, 2026. That level stood EUR 2.45 above mwb research's EUR 21.00 target, leaving the downgrade's valuation concern visible even after the second-quarter improvement. The further course of trading is shown by the continuously updated real-time quote of Stratec stock.

Stratec stock facts

  • Company: Stratec SE
  • ISIN: DE000STRA555
  • WKN: STRA55
  • Ticker: SBS
  • Primary exchange: Xetra
  • Xetra close as of October 12, 2026: EUR 23.45
  • Market capitalization as of October 12, 2026: EUR 278.4 million
  • Sector / Industry: Pharma and Healthcare / Medical Technology
  • Index membership: CDAX Prime All Share and DAXsubsector Medical Technology

Market context: Market report DAX.

More news and analyses on Stratec stock

Disclaimer...

en | DE000STRA555 | STRATEC | boerse | 70308320 | bgmi